Main content
Strength of Statistical Evidence for the Efficacy of Cancer Drugs: A Bayesian Re-Analysis of Randomized Trials Supporting FDA Approval
Date created: | Last Updated:
: DOI | ARK
Creating DOI. Please wait...
Category: Project
Description: We aim to demonstrate the utility of adopting a Bayesian framework to quantify evidential strength and uncertainty for statistical evaluations of benefits of novel cancer drugs at the time of approval. Reanalysing data from the CEIT-Cancer project, we aim to (1) describe evidential strength for clinical trials of drug and biologic products approved for the treatment of cancer in the last two decades; (2) contrast evidential standards between endpoints, accelerated vs. non-accelerated approval, lines of treatment, and type of cancer to describe potential differences in evidential strength.